Cargando…

Treatment patterns in patients using triptan and prophylactic medication: an analysis of clinical practice prior to the introduction of CGRP antagonists

PURPOSE: The newly developed calcitonin gene-related peptide (CGRP) antagonists were recently launched on the US and European market, with Switzerland as the second country worldwide. To enable forthcoming comparisons with established migraine therapy, the aim of this study was to provide a comprehe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huber, Carola A, Agosti, Reto, Näpflin, Markus, Blozik, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657656/ https://www.ncbi.nlm.nih.gov/pubmed/31413619 http://dx.doi.org/10.2147/JPR.S207606

Ejemplares similares

Triptans and CGRP blockade – impact on the cranial vasculature
por: Benemei, Silvia, et al.
Publicado: (2017)

Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting
por: Wirth, Kevin, et al.
Publicado: (2023)

Trends in Micronutrient Laboratory Testing in Switzerland: A 7-Year Retrospective Analysis of Healthcare Claims Data
por: Huber, Carola A, et al.
Publicado: (2020)

Opioid prescriptions after knee replacement: a retrospective study of pathways and prognostic factors in the Swiss healthcare setting
por: Wirth, Kevin, et al.
Publicado: (2023)

Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate
por: Kageneck, Charlotte, et al.
Publicado: (2014)

New CGRP Antagonists
por: Doods, H. N., et al.
Publicado: (2001)

Continuity of Care in Swiss Cancer Patients Using Claims Data
por: Blozik, Eva, et al.
Publicado: (2020)

Continuity of care and treatment intensity at the end of life in Swiss cancer patients
por: Bähler, Caroline, et al.
Publicado: (2023)

Does hospital volume affect outcomes after abdominal cancer surgery: an analysis of Swiss health insurance claims data
por: Wirth, Kevin, et al.
Publicado: (2022)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis
por: Stollberg, Sabrina M., et al.
Publicado: (2023)

Prevalence, trends, and individual patterns of long-term antidepressant medication use in the adult Swiss general population
por: Amrein, Melanie A., et al.
Publicado: (2023)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo
por: Jamaluddin, Aqfan, et al.
Publicado: (2022)

Triptans and troponin: a case report
por: Weder, Claudia R, et al.
Publicado: (2009)

The CGRP-Antagonist BIBN4096BS Discriminates between the Action of α- and β-CGRP In Vitro
por: Wu, Dongmei, et al.
Publicado: (2001)

All triptans are not the same
por: Rapoport, Alan M., et al.
Publicado: (2001)

Clinical experience with triptans
por: Zanchin, Giorgio, et al.
Publicado: (2001)

Different characteristics of triptans
por: Pini, Luigi A., et al.
Publicado: (2004)

Success and failure of triptans
por: Saxena, Pramod R., et al.
Publicado: (2001)

Selecting the preferred triptans
por: McCrory, Douglas C., et al.
Publicado: (2004)

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Triptans in clinical practice: the basic scientist’s point of view
por: Buzzi, M. Gabriella
Publicado: (2001)

Triptans: the experience of a clinical pharmacologist in clinical practice
por: Pini, Luigi Alberto, et al.
Publicado: (2001)

Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists
por: Johnson, Kirk W., et al.
Publicado: (2022)

Best Value for Money in Triptans
por: Curtiss, Frederic R.
Publicado: (2005)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
por: Holland, Philip R., et al.
Publicado: (2018)

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine
por: Chowdhury, Selia, et al.
Publicado: (2023)

Benzodiazepine and Z-Drug Use in Switzerland: Prevalence, Prescription Patterns and Association with Adverse Healthcare Outcomes
por: Landolt, Salome, et al.
Publicado: (2021)

Acute treatment patterns in patients with migraine newly initiating a triptan
por: Lipton, Richard B, et al.
Publicado: (2020)

Pattern of triptans use: a retrospective prescription study in Calabria, Italy
por: Scuteri, Damiana, et al.
Publicado: (2020)

Antidepressant prescription practice and related factors in Switzerland: a cross-sectional analysis of health claims data
por: Haller, Elisa, et al.
Publicado: (2019)

Change in Colorectal Cancer Tests Submitted for Reimbursement in Switzerland 2012–2018: Evidence from Claims Data of a Large Insurance
por: Schneider, Rémi, et al.
Publicado: (2021)

A Novel Nonpeptide CGRP Receptor Antagonist, ‘Compound 1’ (WO98/11128) Is a High Affinity Competitive Antagonist at the CGRP1 Receptor in Human Coronary Arteries
por: Hasbak, P., et al.
Publicado: (2001)

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study
por: Gantenbein, Andreas R, et al.
Publicado: (2021)

The effect of the CGRP receptor antagonist (MK-8825) on the response to trigeminal nociception in rodents
por: Romero-Reyes, M, et al.
Publicado: (2013)

A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine
por: von Mentzer, Bengt, et al.
Publicado: (2020)

Gel-forming antagonist provides a lasting effect on CGRP-induced vasodilation
por: Chang, Chia Lin, et al.
Publicado: (2022)

Use of triptans for the control of headache in bacterial meningitis
por: Wiwanitkit, Viroj
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5ihjrlgkk9pv2u4dahhqhmbm9h